Projects per year
Fingerprint
Dive into the research topics where Suzanah Boyd is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
Live-cell confocal microscope
Atkin, J. (Primary Chief Investigator), Sundaramoorthy, V. (Chief Investigator), Halloran, M. (Chief Investigator), Avolio, A. (Chief Investigator), Butlin, M. (Chief Investigator), Chung, R. (Chief Investigator), Morsch, M. (Chief Investigator), Lee, A. (Chief Investigator), Shi, B. (Chief Investigator), Connor, M. (Chief Investigator), Goodchild, A. (Chief Investigator), Hassan, S. (Chief Investigator), Guillemin, G. (Chief Investigator), Lim, E. (Chief Investigator), Lovejoy, D. (Chief Investigator), Adams, S. (Chief Investigator), Heng, B. (Chief Investigator), McMullan, S. (Chief Investigator), Phillips, J. K. (Chief Investigator), Hildreth, C. (Chief Investigator), Rizos, H. (Chief Investigator), Shahheydari, H. (Research Assistant), Irvine, M. (Research Assistant), Lauter, C. (Research Assistant), Boyd, S. (Research Assistant) & Vickery, K. (Chief Investigator)
12/02/15 → 31/12/15
Project: Research
-
Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment
Lim, S. Y., Boyd, S. C., Diefenbach, R. J. & Rizos, H., 28 Mar 2025, In: Molecular Cancer. 24, 1, p. 1-17 17 p., 99.Research output: Contribution to journal › Review article › peer-review
Open AccessFile4 Citations (Scopus)9 Downloads (Pure) -
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Irvine, M., Stewart, A., Pedersen, B., Boyd, S., Kefford, R. & Rizos, H., 1 Sept 2018, In: Oncogenesis. 7, 9, p. 1-11 11 p., 72.Research output: Contribution to journal › Article › peer-review
Open AccessFile73 Citations (Scopus)50 Downloads (Pure) -
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R., Carlino, M. S. & Rizos, H., May 2017, In: Annals of Oncology. 28, 5, p. 1130-1136 7 p.Research output: Contribution to journal › Article › peer-review
259 Citations (Scopus) -
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
Pupo, G. M., Boyd, S. C., Fung, C., Carlino, M. S., Menzies, A. M., Pedersen, B., Johansson, P., Hayward, N. K., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., 11 May 2017, In: Biomarker Research. 5, 1, p. 1-4 4 p., 17.Research output: Contribution to journal › Article › peer-review
Open AccessFile12 Citations (Scopus)42 Downloads (Pure) -
Circulating tumor DNA as a biomarker in metastatic melanoma patients treated with anti-PD1 antibodies
Lee, J., Boyd, S., Tembe, V., Menzies, A., Long, G., Guminski, A., Kefford, R., Carlino, M. & Rizos, H., 2016, In: Asia-Pacific Journal of Clinical Oncology. 12, Supplement 4, p. 48-49 2 p.Research output: Contribution to journal › Meeting abstract